Details of the Drug

General Information of Drug (ID: DMMYLTI)

Drug Name
Thyrotropin Alfa
Indication
Disease Entry ICD 11 Status REF
Thyroid cancer 2D10 Approved [1]
Therapeutic Class
Diagnostic Agents
Sequence
>Alpha chain
APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC
VAKSYNRVTVMGGFKVENHTACHCSTCYYHKS
>Beta chain
FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR
TVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY
ADMET Property
Elimination
The drug is excreted via kidney and liver []
Half-life
The concentration or amount of drug in body reduced by one-half in 25 +/- 10 hours [2]
Cross-matching ID
PubChem CID
32281
DrugBank ID
DB00024
TTD ID
D0H4TQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thyrotropin receptor (TSHR) TT6NYJA TSHR_HUMAN Binder [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Thyroid
The Studied Disease Thyroid cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thyrotropin receptor (TSHR) DTT TSHR 9.30E-18 -0.72 -1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020898.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34.